To include your compound in the COVID-19 Resource Center, submit it here.

Amgen's Kyprolis meets OS endpoint in Phase III ASPIRE trial for MM

Amgen Inc. (NASDAQ:AMGN) reported additional data from the Phase III ASPIRE trial in 792 patients with relapsed or refractory multiple myeloma (MM) following treatment with 1-3 prior regimens

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE